CINV prevention is critical to managing costs and quality in the value-based care setting1

The Oncology Care Model (OCM)

There is an ongoing shift toward value-based care models such as the OCM, which are intended to improve health outcomes and produce higher quality care, while reducing healthcare expenditures.2,3

Participating OCM practices are compensated for addressing the complex care needs of patients receiving chemotherapy with enhanced services, while maintaining performance accountability2

CINV control remains an unmet need, according to the 2020 Evaluation of the OCM: Performance Periods 1-3

  • There is a need to reduce emergency department visits and hospitalizations due to chemotherapy toxicity4
  • No change in patient-reported experience with care was seen4
For clinics participating in the OCM, uncontrolled CINV may have a substantial impact
Clinical: CINV is a major cause of cancer treatment delay or premature discontinuation5
Economic: CINV can increase the overall cost of cancer care due to associated office visits, ED visits and hospitalization, and additional supportive care6
Humanistic: CINV is associated with reductions in patient quality of life and impairments in activities of daily living7,8
3 CINV-related measures have been proposed for future quality sets9
  • Symptom control during chemotherapy—nausea
  • Appropriate treatment for high and moderate emetic risk
  • Appropriate treatment for low and minimal emetic risk

Considering that more than 1.6 million new cases of cancer are diagnosed each year in the United States, adopting the standards of care established by the OCM can provide significant benefit to both patients and oncology practices3

CINV=chemotherapy-induced nausea and vomiting; ED=emergency department.


  1. Soefje. Am J Manag Care. 2018.
  2. Centers for Medicare & Medicaid Services. Updated June 23, 2015. Accessed December 22, 2020.
  3. Centers for Medicare & Medicaid Services. Oncology Care Model fact sheet. June 29, 2016. Accessed December 23, 2020.
  4. Evaluation of the oncology care model: performance periods 1-3. Abt Associates. May 2020.
  5. Van Laar et al. Support Care Cancer. 2015.
  6. Schwartzberg et al. Am Health Drug Benefits. 2015.
  7. Burke et al. Support Care Cancer. 2011.
  8. Hawkins et al. Clin J Oncol Nurs. 2009.
  9. Consensus core set: medical oncology. Core Quality Measures Collaborative. Updated October 9, 2020. Accessed December 23, 2020.
  10. Schnadig et al. Future Oncol. 2016.
  11. Zhou et al. Ther Clin Risk Manag. 2015.
  12. SUSTOL [prescribing information]. Heron Therapeutics, Inc., 2017.